Big pharma company Merck (NYSE:MRK) has formed a collaboration with an online patient community platform to measure the impact of psoriasis on patients and develop ways to improve outcomes in a sign that pharmaceutical companies are seeing the value in these communities for drug development, according to a company statement. Under the agreement,PatientsLikeMe will work […]
Merck (NYSE:MRK) has acquired a late-stage drug to treat HIV infection in a licensing deal valued at more than $168 million. It also acquired an early stage drug from a Japanese pharmaceutical group for an undisclosed amount. The deal gives the Whitehouse Station, New Jersey pharmaceutical company a novel lipid acyclic nucleoside phosphonate, CMX157, that’s […]
Patient expectations continue to evolve, and healthcare practices that fail to adapt risk more than just revenue—they risk losing trust.
Merck (NYSE:MRK) and Geisinger Health System have initiated a collaboration to develop healthcare IT programs to improve patient adherence and help primary care physicians identify risk factors for certain diseases. It’s an unusual move for Merck, because of the structure and duration of the program. Other companies like Janssen and Sanofi have initiated competitions with […]
The U.S. Food and Drug Administration has turned down, for now, Merck’s (NYSE: MRK) maintenance drug for metastatic bone sarcoma or metastatic soft tissue sarcoma just a few months after an FDA committee voted overwhelmingly against recommending the drug for approval. The drug is made for adults and pediatric patients ages 13 to 17 years […]
Merck (NYSE:MRK) has launched a nonprofit translational research center in San Diego in a move that reflects the dizzy heights of the patent cliffs some Big Pharma companies are facing. The company is planning to spend up to $90 million over seven years on the California Institute for Biomedical Research, or Calibr. The institute will be led by Dr. Peter G. Schultz, who has a reputation as a world-renowned chemist and biotechnology entrepreneur, the company statement said.
U.S. regulators have issued a complete response letter to Merck (NYSE:MRK), which delays the approval of its new drug application for ezetimibe and atorvastatin tablets, an investigational combination medicine. According to a statement from the pharmaceutical giant, the U.S. Food and Drug Administration said additional data was needed, an issue the company said it will […]
FASENRA® (benralizumab) injection, for subcutaneous use, 30 mg is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). FASENRA provides a treatment option for HCPs to consider when managing this challenging disease.
Merck (NYSE:MRK) has received a warning letter from U.S. regulators after failing to conduct a post-marketing study for its blockbuster diabetes drugs Januvia and Janumet within a previously agreed timetable. The U.S. Food and Drug Administration said the drugmaker failed to conduct a three-month pancreatic safety study in a rodent with diabetes that was treated […]
Merck (NYSE: MRK) is to file a new drug application with the U.S. Food and Drug Administration following successful Phase III clinical trial results. The Whitehouse Station, New Jersey pharmaceutical company’s drug, Suvorexant, generated positive results in clinical trials that sought to prove the efficacy of the drug. Peter S. Kim, president of Merck Research […]
The Supreme Court of Canada has ruled against Merck’s (NYSE:MRK) Canadian division in a case focused on the question of what are corporate trade secrets in the drug approval process, according to Canadian media reports. The 10 year-old case pitted the Canadian health department, Health Canada, against Merck Canada. Citing court documents, the Vancouver Sun […]
Inspire Pharmaceuticals (NASDAQ:ISPH) CEO Adrian Adams joined the North Carolina company in the winter of 2010 with goals of expanding its business beyond eye products and commercializing a breakthrough cystic fibrosis treatment. In January, one month shy of Adams one-year anniversary at Inspire’s helm and days removed from announcing a failed clinical trial on the […]
See how Quantum Health is providing the steps to help their members tackle the cost of specialty medications and other drugs.
Merck (NYSE:MRK) is acquiring Raleigh, North Carolina-based Inspire Pharmaceuticals (NASDAQ:ISPH) for $430 million under a definitive agreement announced Tuesday. Under the agreement, a Merck subsidiary will commence a tender offer for all outstanding shares of Inspire at a price of $5 per share cash. That’s 26 percent more than Inspire’s April 4 close of $3.98. […]